Medical/Pharmaceuticals

MedicosBiotech Wins CES 2025 Innovation Award in Digital Health

SEOUL, South Korea, Jan. 7, 2025 /PRNewswire/ -- MedicosBiotech proudly announces its recognition at CES 2025, the world's premier technology event, as a recipient of the prestigious CES Innovation Award in the Digital Health category. This award honors excellence in innovation, technology, and d...

2025-01-08 01:00 3028

Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease

* Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was generally safe and well tolerated in all dose groups, demonstrating a favorable PK profile in validating gut-restrictive properties. * Supported by Insilico's commercially-available generative AI platf...

2025-01-07 22:00 2025

Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the closing ...

2025-01-07 21:00 2081

U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application

* If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins * Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 Part B study, the results of which were presented...

2025-01-07 18:00 2056

Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference

HONG KONG and SAN FRANCISCO, Jan. 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, taking place onJanuary 13, 2025, in San Francisco, California. The company's founder, ...

2025-01-07 11:18 1989

NUS researchers boost chemotherapy uptake in breast cancer treatment with localised magnetic fields

A recent study explained the mechanisms by which pulsed electromagnetic field therapy enhances doxorubicin uptake, paving the way for precision-driven cancer therapies with fewer side effects SINGAPORE, Jan. 6, 2025 /PRNewswire/ -- Researchers at the National University of Singapore (NUS) have d...

2025-01-07 09:33 1719

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

BEIJING, SHANGHAI and BOSTON, Jan. 6, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been publishe...

2025-01-07 08:30 2031

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO),today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focus...

2025-01-07 08:00 1922

VIV™ Ring: The World's 1st Smart Ring with Generative Sleep Aid Sound at CES 2025

* The Intuitive Smart Ring Challenging Oura and Galaxy Ring * Generative Sleep Aid Sound Enhancing Beyond Biometrics Measurement LAS VEGAS ,Jan. 6, 2025 /PRNewswire/ -- VIV Health is thrilled to announce the upcoming launch of the VIV™ Ring, the world's first smart ring equipped with Generative...

2025-01-06 23:30 2163

Datasea Announces Entry into Agreements that Will Place its Acoustic High-Tech Products in a Total of 263 Beauty Stores in Northern China

The New Agreements Projected to Generate Sales of up to 140,000 Units and $11 Million in Revenue by Year End 2025 BEIJING, Jan. 6, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS, "Datasea" or "the Company"), aNevada-based digital technology company specializing in acoustic high-tech and 5G AI m...

2025-01-06 22:45 3919

EMSRUN Medical Celebrates 15 Years of Excellence in Life-Saving Solutions

WUXI, China, Jan. 6, 2025 /PRNewswire/ -- EMSRUN Medical, a leader in tactical, pre-hospital, and civilian emergency medical solutions, marks its 15th anniversary this year. Since its establishment in 2010, the company has built an outstanding reputation for delivering critical solutions to comba...

2025-01-06 22:10 1847

Technoderma Medicines Completes Positive Ph2a Proof- of Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis

CHENGDU, China, Jan. 6, 2025 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment in patients with Atopic Dermatitis (AD). Th...

2025-01-06 21:00 1857

Concord Medical Announces Result of 2024 Annual General Meeting

BEIJING, Jan. 6, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it held its 2024 annual general meeting of shar...

2025-01-06 20:30 3335

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

* Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization * The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, anddata is ...

2025-01-06 20:00 1810

Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program

SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an investigatio...

2025-01-06 18:05 2079

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization

* Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance * Marks a key step forward for the world's first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic focus on entering the Ameri...

2025-01-03 21:15 5133

GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer

SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment ofJie Jia, Ph.D., as Chief Operating Officer (COO), effective on the date of this press release. Dr. Jia, Jie brings over 20 years of...

2025-01-03 15:30 3311

Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene

CAMBRIDGE, Mass., Jan. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced that BeiGene. Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization right...

2025-01-03 13:30 2415

Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044

WUHAN, China, Jan. 2, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing inAustralia on Dec 30, 2024 for Phase 1 cl...

2025-01-03 01:43 2780

Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers

SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, will present its latest breakthrough immunocytokine, FP008, onJan 14, 2025, at the Biotech Showcase investor conference, following J.P. Morgan Healthcare Week. This ...

2025-01-02 17:17 1750
1 ... 57585960616263 ... 251

Week's Top Stories